AstraZenca Pharma India

ASTRAZEN

₹ 8,600.03

- ₹ 305.27

3.43%

Healthcare

₹ 0.00

(%)1D

Updated: 25 Apr 2025, 03:31:26 pm IST

Stock Score

Open Price

₹ 8,838.34

Prev. Close

₹ 8,905.30

₹ 8,422.14

Day Low

₹ 8,870.87

Day High

₹ 5,061.55

52 Week Low

₹ 9,151.25

52 Week High

Quick Bite

Price To Earnings Ratio 133.13	Sector PE 65.09
PB Ratio 30.34	Sector PB 8.49
EPS 64.60	Dividend Yield 0.45
Today's Volume 18.440 K	5 Day Avg. Volume 19.335 K
PEG Ratio 2.12	Market Cap. ₹ 21,870.00 Cr.

News & Events

About AstraZenca Pharma India

AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company's DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).

AstraZenca Pharma India Share Price

AstraZeneca Pharma India Limited is an Indian biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolic; oncology and respiratory diseases. The company operates through the healthcare segment. The company manufactures, markets and distributes pharmaceuticals and provides clinical research services to a foreign group company. Its therapeutic offering in the CVRM business includes Forxiga (Dapagliflozin) in heart failure and chronic kidney disease. Its approvals in the oncology business include Imfinz (Durvalumab) for the treatment of bile duct carcinoma and Lynparza (Olaparib) for early breast cancer. The company has a range of oral diabetes medications that fall into two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The company's DPP4 offering consists of the Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metform) brands.

AstraZenca Pharma India FAQs

How to Buy AstraZenca Pharma India Share?

To purchase AstraZenca Pharma India shares, you can open a Demat & Trading account through a broker or financial institution. Once your account is set up and funded, search for AstraZenca Pharma India (ticker symbol: ASTRAZEN) on the trading platform provided by your broker and purchase the shares.

What's AstraZenca Pharma India share price today?

The stock price of AstraZenca Pharma India as of 26 Apr 2025 is ₹8,600.03

What is the Market Cap of AstraZenca Pharma India?

Market capitalisation represents the total market value of a company's outstanding shares. As of 26 Apr 2025, AstraZenca Pharma India (ticker symbol: ASTRAZEN) has a market capitalisation of approximately ₹2,18,70,00,00,000.00

What is the PE and PB ratio of AstraZenca Pharma India?

AstraZenca Pharma India Ltd's price-to-book ratio as of 26 Apr 2025 is 30.34, reflecting the market's valuation compared to its asset value. As of 26 Apr 2025, the trailing twelve months P/E (price-to-earnings) ratio is 133.13, indicating the market values the company at around ₹133.13 for every ₹1 of earnings

What is the 52 Week High and Low of AstraZenca Pharma India Share?

AstraZenca Pharma India Ltd (ASTRAZEN) hit its 52-week high at ₹9,151.25, and its 52-week low at ₹5,061.55.

Begin your investment journey today

View All Global Indices